Cargando…
Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look!
BACKGROUND: The risk of thromboembolic events is higher among cancer patients, especially in patients undergoing chemotherapy. Cisplatin-based regimens claim to be associated with a very high thromboembolic rate. In this study, we report on our own experience with thrombosis among patients on active...
Autores principales: | Abdel-Razeq, Hikmat, Mansour, Asem, Abdulelah, Hazem, Al-Shwayat, Anas, Makoseh, Mohammad, Ibrahim, Mohammad, Abunasser, Mahmoud, Rimawi, Dalia, Al-Rabaiah, Abeer, Alfar, Rozan, Abufara, Alaa’, Ibrahim, Alaa, Bawaliz, Anas, Ismael, Yousef |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831696/ https://www.ncbi.nlm.nih.gov/pubmed/29507532 http://dx.doi.org/10.1186/s12959-018-0161-9 |
Ejemplares similares
-
The Application of the Lymphoma International Prognostic Index to Predict Venous Thromboembolic Events in Diffuse Large B-Cell Lymphoma Patients
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2021) -
Inferior vena cava filters in cancer patients: to filter or not to filter
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2011) -
The Application of the ThroLy Risk Assessment Model to Predict Venous
Thromboembolism in Patients with Diffuse Large B-Cell Lymphoma
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2021) -
The application of clinical variables and models to predict pulmonary embolism in cancer patients: a comprehensive single cancer center experience
por: Mansour, Asem, et al.
Publicado: (2013) -
Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2018)